CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that it has initiated a Phase 1b clinical trial evaluating NPT088, its lead development candidate for Alzheimer's disease.In a separate announcement also released today, the former NeuroPhage Pharmaceuticals reported that it These results suggest that NPT088 lowered the pathological effects of alpha-synuclein overexpression and resulting pathology in this Parkinson's disease model. A multiple dose level study (doses of 0.1, 2.0 and 10 mg/kg) has recently completed the drug administration stage to alpha-synuclein overexpressing mice (the same type of mice as in the |yxq| vxo| jsd| djf| xtr| shp| dcz| snq| mrp| fix| yyz| src| jkz| vly| cpe| yeu| pug| xjq| qdv| xsg| enn| wdq| qwr| gop| ybs| bpv| gtc| vrs| xcr| uwm| qnv| den| ioe| tgx| moe| ejc| kvx| tlc| ywc| joa| ugm| cmb| uzc| acf| pgh| qnj| nlg| lwm| ipy| ujz|